PEPTONIC MEDICAL (28L) - Net Assets
Based on the latest financial reports, PEPTONIC MEDICAL (28L) has net assets worth €38.24 Million EUR (≈ $44.71 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€65.92 Million ≈ $77.06 Million USD) and total liabilities (€27.67 Million ≈ $32.35 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read PEPTONIC MEDICAL (28L) financial obligations for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €38.24 Million |
| % of Total Assets | 58.02% |
| Annual Growth Rate | -7.88% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 36.81 |
PEPTONIC MEDICAL - Net Assets Trend (2021–2025)
This chart illustrates how PEPTONIC MEDICAL's net assets have evolved over time, based on quarterly financial data. Also explore PEPTONIC MEDICAL assets under control for the complete picture of this company's asset base.
Annual Net Assets for PEPTONIC MEDICAL (2021–2025)
The table below shows the annual net assets of PEPTONIC MEDICAL from 2021 to 2025. For live valuation and market cap data, see PEPTONIC MEDICAL stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €38.24 Million ≈ $44.71 Million |
-21.23% |
| 2024-12-31 | €48.55 Million ≈ $56.76 Million |
-35.54% |
| 2023-12-31 | €75.32 Million ≈ $88.06 Million |
+59.95% |
| 2022-12-31 | €47.09 Million ≈ $55.06 Million |
-11.34% |
| 2021-12-31 | €53.12 Million ≈ $62.10 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to PEPTONIC MEDICAL's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 15446900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €416.81 Million | 1089.88% |
| Total Equity | €38.24 Million | 100.00% |
PEPTONIC MEDICAL Competitors by Market Cap
The table below lists competitors of PEPTONIC MEDICAL ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Randgold Exploration
JSE:RNG
|
$4.15 Million |
|
Aeeris Ltd
AU:AER
|
$4.15 Million |
|
GGL Resources Corp
V:GGL
|
$4.15 Million |
|
Marshalls PLC
LSE:MSLH
|
$4.15 Million |
|
Onfolio Holdings Inc
NASDAQ:ONFO
|
$4.14 Million |
|
Click Holdings Limited
NASDAQ:CLIK
|
$4.14 Million |
|
Halo Technologies Holdings Ltd
AU:HAL
|
$4.13 Million |
|
GLOW LIFETECH CORP.
F:9DO
|
$4.13 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in PEPTONIC MEDICAL's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 48,552,000 to 38,244,000, a change of -10,308,000 (-21.2%).
- Net loss of 22,495,000 reduced equity.
- Other factors increased equity by 12,187,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-22.50 Million | -58.82% |
| Other Changes | €12.19 Million | +31.87% |
| Total Change | €- | -21.23% |
Book Value vs Market Value Analysis
This analysis compares PEPTONIC MEDICAL's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.06x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €0.10 | €0.00 | x |
| 2022-12-31 | €0.07 | €0.00 | x |
| 2023-12-31 | €0.03 | €0.00 | x |
| 2024-12-31 | €0.01 | €0.00 | x |
| 2025-12-31 | €0.00 | €0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently PEPTONIC MEDICAL utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -58.82%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -152.12%
- • Asset Turnover: 0.22x
- • Equity Multiplier: 1.72x
- Recent ROE (-58.82%) is above the historical average (-91.20%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -138.73% | -232.87% | 0.37x | 1.59x | €-79.00 Million |
| 2022 | -78.27% | -84.47% | 0.51x | 1.82x | €-41.57 Million |
| 2023 | -56.54% | -114.74% | 0.35x | 1.42x | €-50.12 Million |
| 2024 | -123.64% | -223.24% | 0.38x | 1.45x | €-64.88 Million |
| 2025 | -58.82% | -152.12% | 0.22x | 1.72x | €-26.32 Million |
Industry Comparison
This section compares PEPTONIC MEDICAL's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $6,783,361,465
- Average return on equity (ROE) among peers: -105.59%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| PEPTONIC MEDICAL (28L) | €38.24 Million | -138.73% | 0.72x | $4.14 Million |
| SHANG.FOS.PHARM.GR.H YC 1 (08HH) | $54.11 Billion | 6.89% | 0.98x | $1.21 Billion |
| Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (2TZ) | $6.51 Billion | 11.81% | 0.39x | $692.11 Million |
| WEST ISLAND BRANDS INC. (39N0) | $3.27 Million | -157.21% | 0.88x | $1.34 Million |
| AYURCANN HOLDINGS CORP. (3ZQ0) | $534.88K | -741.80% | 26.77x | $97.35K |
| CERENO SCIENTIFIC AB B (4A1) | $191.93 Million | -51.86% | 1.16x | $157.72 Million |
| MAPLE LEAF GREEN WORLD (4HV0) | $-8.51 Million | 0.00% | 0.00x | $504.30K |
| LORDS CO. WORLDW. HOLD. (4XM) | $-1.01 Million | 0.00% | 0.00x | $134.78K |
| RED LIGHT HOLLAND CORP. (4YX) | $20.26 Million | -37.64% | 0.19x | $13.93 Million |
| EQL PHARMA AB (7JK) | $221.03 Million | 19.51% | 2.66x | $84.75 Million |
About PEPTONIC MEDICAL
PEPTONIC medical AB (publ), a medical technology company, develops and sells intimate self-care products for women. The company offers products under the VagiVital brand, including a moisturizing gel for atrophy; an intimate calming gel for rapid relief of itching and irritation; moisturizing lubricant; a pH-balancing intimate wash/conditioner; self-test kits for diagnosing pre-menopause, menopau… Read more